Cited by 690Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 46 of the 51 references it cites were found in a registry or an index.

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

Open access

Scagliotti, Giorgio, Hanna, Nasser, Fossella, Frank, Sugarman, Katherine, Blatter, Johannes, Peterson, Patrick, Simms, Lorinda, Shepherd, Frances A.·2009·The Oncologist

DOI 10.1634/theoncologist.2008-0232

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. METHODS: One study tested pemetrexed versus docetaxel in previously treated patients (n = 571) and the other tested cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced NSCLC. Cox proportional hazard models were used to test for covariate-adjusted treatment-by-histology interactions (THIs) for overall survival (OS) and progression-free survival (PFS). For each histologic subgroup, the Kaplan-Meier method was used to estimate unadjusted within-arm medians, and Cox models were used to estimate covariate-adjusted between-arm hazard ratios (HRs). RESULTS: In both studies, treatment arms were well balanced for histology. THIs were statistically significant (p < .005) for both OS and PFS. Nonsquamous patients treated with pemetrexed-based therapy experienced longer survival than the comparators (HR, 0.78 and 0.84, respectively), whereas squamous patients had shorter survival (HR, 1.56 and 1.23, respectively). Whereas the efficacy of pemetrexed regimens differed according to histology, it did not differ for docetaxel or for cisplatin plus gemcitabine. Pemetrexed was well tolerated across histologic groups. CONCLUSIONS: The consistency of these results across studies confirms the predictive effect of histology for pemetrexed and the survival advantage for pemetrexed in patients with nonsquamous histology. These analyses suggest pemetrexed should not be recommended for the treatment of squamous cell carcinoma, but, because of efficacy and safety advantages, pemetrexed may be preferable to other agents for treatment of patients with nonsquamous NSCLC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2008-0232

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,524
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citation
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Self-citation
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079

Show all 51 references

Research works printed but not linked: 2

Jiroutek, 1998, Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981–1992, Proc Am Soc Clin Oncol, 17, 461a
National Cancer Institute, 1999, Common Toxicity Criteria v2.0 (CTC)

Sorted by citations

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
Travis, W. D., Brambilla, E. M., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Schil, P. E. V., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,834
Self-citation
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
Camidge, D. R., Bang, Y., Kwak, E. L., Iafrate, A. J., Varella‐Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S. I., Kim, D., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70344-3 · Cited by 1,267
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Self-citation
Lung cancer: Biology and treatment options
Lemjabbar‐Alaoui, H., Hassan, O. U., Yang, Y., & Buchanan, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,067
Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features
Yu, K.-H., Zhang, C., Berry, G. J., Altman, R. B., Ré, C., Rubin, D. L., & Snyder, M. (2016) · Nature Communications · doi:10.1038/ncomms12474 · Cited by 972
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K. M., & Felip, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds226 · Cited by 940
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Non-small-cell lung cancer
Goldstraw, P. G., Ball, D., Jett, J. R., Chevalier, T. L., Lim, E. K. S., Nicholson, A. G., & Shepherd, F. A. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62101-0 · Cited by 741
Self-citation
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Reck, M., Popat, S., Reinmuth, N., Ruysscher, D. D., Kerr, K. M., & Peters, S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu199 · Cited by 688
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Hendriks, L. E. L., Kerr, K. M., Menis, J., Mok, T. S. K., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 685
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Paz-Ares, L., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70063-3 · Cited by 610
New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials
Travis, W. D., Brambilla, E. M., & Riely, G. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9270 · Cited by 622
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
Quintanal-Villalonga, À., Chan, J. M., Yu, H. A., Pe’er, D., Sawyers, C. L., Sen, T., & Rudin, C. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0340-z · Cited by 585
Pathology of Lung Cancer
Travis, W. D. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.08.005 · Cited by 541
Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification
Travis, W. D., Brambilla, E. M., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Ishikawa, Y., Wistuba, I. I., Flieder, D. B., Franklin, W. A., et al. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0263-ra · Cited by 423
Genetic alterations defining NSCLC subtypes and their therapeutic implications
Pikor, L. A., Ramnarine, V. R., Lam, S., & Lam, W. L. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.025 · Cited by 375
Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology
Wu, W., Parmar, C., Großmann, P., Quackenbush, J. F., Lambin, P., Bussink, J., Mak, R. H., & Aerts, H. J. W. L. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00071 · Cited by 378
The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer
Langer, C. J., Besse, B., Gualberto, A., Brambilla, E., & Soria, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8126 · Cited by 308
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 296
Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer
Scagliotti, G. V., Brodowicz, T., Shepherd, F. A., Zielinski, C. C., Vansteenkiste, J., Manegold, C., Simms, L., Fossella, F. V., Sugarman, K. P., & Belani, C. P. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f7c6d4 · Cited by 252
Self-citation
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
Camidge, D. R., Kono, S. A., Lu, X. J. D., Okuyama, S., Barón, A. E., Oton, A. B., Davies, A. M., Varella‐Garcia, M., Franklin, W. A., & Doebele, R. C. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820cf053 · Cited by 239
Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing
Rekhtman, N., Brandt, S. M., Sigel, C., Friedlander, M. A., Riely, G. J., Travis, W. D., Zakowski, M. F., & Moreira, A. L. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820517a3 · Cited by 236
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
Socinski, M. A., Obasaju, C. K., Gandara, D. R., Hirsch, F. R., Bonomi, P., Bunn, P. A., Kim, E. S., Langer, C. J., Natale, R. B., Novello, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.111 · Cited by 227
Histologic subtype classification of non-small cell lung cancer using PET/CT images
Han, Y. K., Ma, Y., Wu, Z., Zhang, F., Zheng, D., Liu, X., Tao, L., Liang, Z., Yang, Z., Li, X., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04771-5 · Cited by 218
FGFR1 Amplification in Squamous Cell Carcinoma of The Lung
Heist, R. S., Mino-Kenudson, M. A., Sequist, L. V. D., Tammireddy, S., Morrissey, L., Christiani, D. C., Engelman, J. A., & Iafrate, A. J. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826aed28 · Cited by 204
Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology: A Paradigm Shift
Travis, W. D., Rekhtman, N., Riley, G. J., Geisinger, K. R., Asamura, H., Brambilla, E. M., Garg, K., Hirsch, F. R., Noguchi, M., Powell, C. A., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d57f6e · Cited by 193
Self-citation
Genetic Changes in Squamous Cell Lung Cancer: A Review
Heist, R. S., Sequist, L. V. D., & Engelman, J. A. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31824cc334 · Cited by 197
Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial
Ramlau, R., Горбунова, В. А., Ciuleanu, T., Novello, S., Özgüroğlu, M., Göksel, T., Baldotto, C. S. D. R., Bennouna, J., Shepherd, F. A., Le-Guennec, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.6932 · Cited by 186
Self-citation
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis
Zhao, Y., Liu, J., Cai, X., Pan, Z., Liu, J., Yin, W., Chen, H., Xie, Z., Liang, H., Wang, W., et al. (2019) · BMJ · doi:10.1136/bmj.l5460 · Cited by 170
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer
Vansteenkiste, J., Canon, J.-L. R., de Braud, F., Grossi, F., Pas, T. M. D., Gray, J. E., Su, W., Felip, E., Yoshioka, H., Gridelli, C., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000607 · Cited by 163
A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
Hainsworth, J. D., Cebotaru, C. L., Kanarev, V., Ciuleanu, T., Damyanov, D., Stella, P. J., Ganchev, H., Pover, G. M., Morris, C. D., & Tzekova, V. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e8b3a3 · Cited by 162
PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer
Zinner, R., Obasaju, C. K., Spigel, D. R., Weaver, R., Beck, J. T., Waterhouse, D. M., Modiano, M., Hrinczenko, B. W., Nikolinakos, P. G., Liu, J., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000366 · Cited by 161
Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based Chemotherapy
Righi, L., Papotti, M. G., Ceppi, P., Billè, A., Bacillo, E., Molinaro, L., Ruffini, E., Scagliotti, G. V., & Selvaggi, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9275 · Cited by 159
Self-citation
Treatment of advanced non small cell lung cancer.
Bareschino, M. A., Schettino, C., Rossi, A., Maione, P., Sacco, P. C., Zeppa, R., & Gridelli, C. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.12.08 · Cited by 161
Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis
Zhao, Y., Wang, R., Shen, X., Pan, Y., Cheng, C., Li, Y., Shen, L., Zhang, Y., Li, H., Zheng, D., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-015-5043-9 · Cited by 152
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
Akamatsu, H., Ninomiya, K., Kenmotsu, H., Morise, M., Daga, H., Goto, Y., Kozuki, T., Miura, S., Sasaki, T., Tamiya, A., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01431-z · Cited by 149
Treatment of Lung Cancer
Gadgeel, S. M., Ramalingam, S. S., & Kalemkerian, G. P. (2012) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2012.06.003 · Cited by 144
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 138
Efficacy of gefitinib for non‐adenocarcinoma non‐small‐cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports
Shukuya, T., Takahashi, T., Kaira, R., Ono, A., Nakamura, Y., Tsuya, A., Kenmotsu, H., Naito, T., Kaira, K., Murakami, H., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01887.x · Cited by 137
Lung cancer stem cells: tools and targets to fight lung cancer
Eramo, A., Haas, T. L., & Maria, R. D. (2010) · Oncogene · doi:10.1038/onc.2010.207 · Cited by 140
miR-141 and miR-200c as Markers of Overall Survival in Early Stage Non-Small Cell Lung Cancer Adenocarcinoma
Tejero, R., Navarro, A., Campayo, M., Viñolas, N., Marrades, R. M., Cordeiro, A., Ruíz-Martínez, M., Santasusagna, S., Molins, L., Ramírez, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101899 · Cited by 134
Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer
Dønnem, T., Andersen, S., Al-Shibli, K. I., Al‐Saad, S., Busund, L., & Bremnes, R. M. (2010) · Cancer · doi:10.1002/cncr.25551 · Cited by 131
Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy
Sun, J., Han, J., Ahn, J. S., Park, K., & Ahn, M. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182208ea8 · Cited by 124
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
Olaussen, K. A., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw321 · Cited by 124
Large‐scale comparative analyses of immunomarkers for diagnostic subtyping of non‐small‐cell lung cancer biopsies
Warth, A., Muley, T., Herpel, E., Meister, M. A., Herth, F. J. F., Schirmacher, P., Weichert, W., Hoffmann, H., & Schnabel, P. A. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04308.x · Cited by 120
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials
Wheatley‐Price, P., Blackhall, F. H., Lee, S. M., Ma, C., Ashcroft, L., Jitlal, M., Qian, W., Hackshaw, A. K., Rudd, R., Booton, R., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq067 · Cited by 119
Self-citation
Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma
Qu, Y., Emoto, K., Eguchi, T., Aly, R. G. M., Zheng, H., Chaft, J. E., Tan, K. S., Jones, D. R., Kris, M. G., Adusumilli, P. S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.017 · Cited by 122
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
Shaw, A. T., Varghese, A. M., Solomon, B., Costa, D. B., Novello, S., Mino-Kenudson, M. A., Awad, M. M., Engelman, J. A., Riely, G. J., Monica, V., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds242 · Cited by 120
Self-citation
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed
Chen, C., Chang, Y., Shih, J., Lin, J., Chen, K., Yang, C.-H., Yu, C., & Yang, P. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.024 · Cited by 113
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
Yoh, K., Hosomi, Y., Kasahara, K., Yamada, K., Takahashi, T., Yamamoto, N., Nishio, M., Ohe, Y., Koue, T., Nakamura, T., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.019 · Cited by 110
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non–Small-Cell Lung Cancer
Kenmotsu, H., Yamamoto, N., Yamanaka, T., Yoshiya, K., Takahashi, T., Ueno, T., Goto, K., Daga, H., Ikeda, N., Sugio, K., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02674 · Cited by 108
Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer
Otterson, G. A., Villalona-Calero, M. A., Hicks, W. J., Pan, X. J., Ellerton, J. A., Gettinger, S. N., & Murren, J. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3015 · Cited by 108
Rare cancers: a sea of opportunity
Boyd, N., Dancey, J. E., Gilks, C. B., & Huntsman, D. D. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00386-1 · Cited by 107
Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice
Taverna, S., Giallombardo, M., Bazo, I. G., Carreca, A. P., Castiglia, M., Chacartegui, J. J., Araújo, A., Alessandro, R., Pauwels, P., Peeters, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7638 · Cited by 112
Prognostic Impact of MiR-155 in Non-Small Cell Lung Cancer Evaluated by in Situ Hybridization
Dønnem, T., Eklo, K., Berg, T., Sørbye, S. W., Lønvik, K., Al‐Saad, S., Al-Shibli, K. I., Andersen, S., Stenvold, H., Bremnes, R. M., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-6 · Cited by 106
Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer
Lu, S., Kong, H., Hou, Y., Ge, D., Huang, W., Ou, J., Yang, D., Zhang, L., Wu, G., Song, Y., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.027 · Cited by 106
Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype.
Sorrentino, C., & Carlo, E. D. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0400oc · Cited by 100
MicroRNA Signatures in Tumor Tissue Related to Angiogenesis in Non-Small Cell Lung Cancer
Dønnem, T., Fenton, C. G., Lønvik, K., Berg, T., Eklo, K., Andersen, S., Stenvold, H., Al-Shibli, K. I., Al‐Saad, S., Bremnes, R. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029671 · Cited by 104
Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer
Nizzoli, R., Tiseo, M., Gelsomino, F., Bartolotti, M., Majori, M., Ferrari, L., Filippo, M. D., Rindi, G., Silini, E. M., Guazzi, A., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820b86cb · Cited by 102
Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years
Čufer, T., Ovčariček, T., & O'Brien, M. E. R. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.021 · Cited by 104
Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens
Bubendorf, L., Lantuéjoul, S., de Langen, A. J., & Thunnissen, E. (2017) · European Respiratory Review · doi:10.1183/16000617.0007-2017 · Cited by 102
Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma
Lockwood, W. W., Chari, R., Coe, B. P., Thu, K. L., Garnis, C., Malloff, C. A., Campbell, J., Williams, A. C., Hwang, D., Zhu, C.-Q., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000315 · Cited by 89
Personalized medicine for lung cancer: new challenges for pathology
Kerr, K. M. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.03854.x · Cited by 104
Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
Zielinski, C. C., Knapp, S., Mascaux, C., & Hirsch, F. R. (2013) · Annals of Oncology · doi:10.1093/annonc/mds647 · Cited by 97
Downregulation of DNMT3A by miR-708-5p Inhibits Lung Cancer Stem Cell–like Phenotypes through Repressing Wnt/β-catenin Signaling
Liu, T., Wu, X., Chen, T., Luo, Z., & Hu, X. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1169 · Cited by 97
A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer
Ellis, P. M., Blais, N., Soulieres, D., Ionescu, D. N., Kashyap, M., Liu, G., Melosky, B., Reiman, T., Romeo, P., Shepherd, F. A., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318220cb8e · Cited by 96
Self-citation
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Azzoli, C. G., Giaccone, G., & Temin, S. (2010) · Journal of Oncology Practice · doi:10.1200/jop.091065 · Cited by 96
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer
Pereira, J. R., Kim, J.-H., Magallanes, M., Lee, K. H., Wang, J., Ganju, V., Martínez-Barrera, L. M., Barraclough, H., Kooten, M. V., & Orlando, M. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318226b5fa · Cited by 93
Real‐world chemotherapy treatment patterns in metastatic non–small cell lung cancer: Are patients undertreated?
Sacher, A. G., Le, L. W., Lau, A., Earle, C. C., & Leighl, N. B. (2015) · Cancer · doi:10.1002/cncr.29386 · Cited by 82
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies
Ou, S. I., & Zell, J. A. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b28fb9 · Cited by 79
Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer
Doebele, R. C., Spigel, D. R., Tehfe, M. A., Thomas, S. P., Reck, M., Verma, S., Eakle, J. F., Bustin, F., Goldschmidt, J. H., Cao, D., et al. (2014) · Cancer · doi:10.1002/cncr.29132 · Cited by 77
New Radiotherapy and Chemoradiotherapy Approaches for Non–Small-Cell Lung Cancer
Salama, J. K., & Vokes, E. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5064 · Cited by 78
Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes
Goeree, R. A., Villeneuve, J., Goeree, J., Penrod, J. R., Orsini, L. S., & Monfared, A. A. T. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2016.1151432 · Cited by 79
Classification of Lung Cancer
Travis, W. D. (2011) · Seminars in Roentgenology · doi:10.1053/j.ro.2011.02.003 · Cited by 80
Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Cohen, M. H., Johnson, J. R., Chattopadhyay, S., Tang, S. W., Justice, R. L., Sridhara, R., & Pazdur, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0257 · Cited by 74
The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.
Zugazagoitia, J., Enguita, A. B., Nuñez, J. A., Iglesias, L., & Ponce, S. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2014.01.27 · Cited by 73
Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer
Fakih, M., & Vincent, M. D. (2010) · Current Oncology · doi:10.3747/co.v17is1.615 · Cited by 152
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung
Monica, V., Scagliotti, G. V., Ceppi, P., Righi, L., Cambieri, A., Iacono, M. L., Saviozzi, S., Volante, M., Novello, S., & Papotti, M. G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1641 · Cited by 72
Self-citation
Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
Klein, R. W., Wielage, R. C., Muehlenbein, C. E., Liepa, A. M., Babineaux, S. M., Lawson, A., & Schwartzberg, L. S. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e15d16 · Cited by 71
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
Gridelli, C., Ardizzoni, A., Douillard, J., Hanna, N. H., Manegold, C., Perrone, F., Pirker, R., Rosell, R., Shepherd, F. A., Petris, L. D., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.11.018 · Cited by 70
Self-citation
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
Scagliotti, G., Kang, J. H., Smith, D. C., Rosenberg, R. K., Park, K., Kim, S.-W., Su, W., Boyd, T. E., Richards, D., Novello, S., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0368-1 · Cited by 70
Self-citation
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials
Maïo, M. D., Lama, N., Morabito, A., Smit, E. F., Georgoulias, V., Takeda, K., Quoix, É., Hatzidaki, D., Wachters, F. M., Gebbia, V., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.013 · Cited by 69
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials
Gridelli, C., Morabito, A., Cavanna, L., Luciani, A., Maione, P., Bonanno, L., Filipazzi, V., Leo, S., Cinieri, S., Ciardiello, F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8390 · Cited by 69
Strategies for Prolonged Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
Fidias, P. M., & Novello, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7074 · Cited by 67
Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study
Moro‐Sibilot, D., Smit, E. F., de Castro, J., Leśniewski-Kmak, K., Aerts, J. G. J. V., Villatoro, R., Kraaij, K., Nacerddine, K., Dyachkova, Y., Smith, K. T., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.02.011 · Cited by 68
Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
Patel, J. D., Bonomi, P., Socinski, M. A., Govindan, R., Hong, S., Obasaju, C. K., Pennella, E. J., Girvan, A. C., & Guba, S. C. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.035 · Cited by 67
ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer
Papadaki, C., Sfakianaki, M., Ioannidis, G., Lagoudaki, E. D., Trypaki, M., Tryfonidis, K., Mavroudis, D., Stathopoulos, E. N., Georgoulias, V., & Souglakos, J. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318244bdd4 · Cited by 67
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
Novello, S., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.11.015 · Cited by 66
What’s new in non-small cell lung cancer for pathologists the importance of accurate subtyping, EGFR mutations and ALK rearrangements
Cooper, W. A., O'Toole, S. A., Boyer, M. J., Horvath, L. G., & Mahar, A. M. (2011) · Pathology · doi:10.1097/pat.0b013e328342629d · Cited by 67
Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor
Berge, E. M., & Doebele, R. C. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.006 · Cited by 65
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma
Kawachi, H., Kunimasa, K., Kukita, Y., Nakamura, H., Honma, K., Kawamura, T., Inoue, T., Tamiya, M., Kuhara, H., Nishino, K., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0311 · Cited by 65
Personalized Therapy for Lung Cancer
Moreira, A. L., & Eng, J. (2014) · CHEST Journal · doi:10.1378/chest.14-0713 · Cited by 67
Validation of Interobserver Agreement in Lung Cancer Assessment: Hematoxylin-Eosin Diagnostic Reproducibility for Non–Small Cell Lung Cancer: The 2004 World Health Organization Classification and Therapeutically Relevant Subsets
Grilley‐Olson, J. E., Hayes, D. N., Moore, D., Leslie, K. O., Wilkerson, M. D., Qaqish, B. F., Hayward, M. C., Cabanski, C. R., Yin, X., Socinski, M. A., et al. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0033-oa · Cited by 63
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment
Langer, C. J., Obasaju, C. K., Bunn, P. A., Bonomi, P., Gandara, D. R., Hirsch, F. R., Kim, E. S., Natale, R. B., Novello, S., Paz-Ares, L. G., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.138 · Cited by 62
Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures.
Carnio, S., Novello, S., Papotti, M. G., Iacono, M. L., & Scagliotti, G. V. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.10.05 · Cited by 63
Self-citation

Authors: Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., & Shepherd, F. A.
Affiliations: University of Turin (IT)
Indiana University Indianapolis (US)
The University of Texas MD Anderson Cancer Center (US)
Eli Lilly (United States) (US)
Eli Lilly (Germany) (DE)
Eli Lilly (Canada) (CA)
University of Toronto (CA)
Corresponding author: Scagliotti, Giorgio
ORCID: Scagliotti, Giorgio
Hanna, Nasser
Peterson, Patrick
Shepherd, Frances A.
Venue: The Oncologist
Publisher: Oxford University Press (OUP)
Published: 2009-02-16
Volume: 14
Issue: 3
Pages: 253-263
ISSN: 1083-7159 (ISSN-L)
1549-490X
DOI: 10.1634/theoncologist.2008-0232
OpenAlex: W2139939379
Cited by: 690
References: 51
Citations by year: 2026: 5 · 2025: 8 · 2024: 10 · 2023: 15 · 2022: 21 · 2021: 15 · 2020: 27 · 2019: 29 · 2018: 30 · 2017: 42 · 2016: 46 · 2015: 41 · 2014: 69 · 2013: 72 · 2012: 71
FWCI: 72.97
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: The Oncologist (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Funders: Eli Lilly and Company
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: pemetrexed, non-small cell lung cancer, tumor histology, squamous cell carcinoma, docetaxel, overall survival, progression-free survival, predictive biomarkers
MeSH terms: Pemetrexed, Docetaxel, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Randomized Controlled Trials as Topic, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks